Investors interested in Medical Info Systems stocks are likely familiar with Definitive Healthcare Corp. (DH) and GE HealthCare Technologies (GEHC) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores ...

GE HealthCare Technologies Inc. (GEHC) is scheduled to report third-quarter 2024 results on Oct. 30, before market open. In the last reported quarter, the company's adjusted earnings per share of $1 beat the Zacks Consensus Estimate by 0.27%. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's take a look at how things might have shaped up for GEHC prior to the announcement. Factors at Play GE HealthCare's performance is expected to have been hurt by a lower volume of sales durin ...

Core Viewpoint - GE HealthCare Technologies (GEHC) has launched CareIntellect for Oncology, a cloud-first application that integrates multi-modal patient data using generative AI to enhance clinical decision-making and patient care. Group 1: Product Launch and Features - CareIntellect for Oncology will initially focus on breast and prostate cancer, providing a comprehensive view of patient data to streamline treatment assessments and clinical trial eligibility [1][4] - The application organizes both structured and unstructured data, reducing the time clinicians spend on gathering patient histories from multiple systems [2][3] - It will be available to U.S. consumers in 2025, with plans for expansion to Canada, the UK, and Ireland [4] Group 2: Market Performance and Financials - Following the announcement, GEHC shares fell by 1.7% to $89.80, but have increased by 16.2% year-to-date, outperforming the industry which declined by 9.6% [2] - GEHC has a market capitalization of $41.01 billion and an earnings yield of 4.74%, significantly higher than the industry's negative yield of 8.78% [2] Group 3: Industry Trends and Opportunities - The global generative AI in healthcare market is projected to grow from $1.6 billion in 2022 to over $30.4 billion by 2032, with a CAGR of 34.9% [5] - The increasing volume of healthcare data and the shortage of healthcare workers are driving the adoption of AI solutions in clinical settings [5] Group 4: Recent Developments in AI - GEHC has launched Versana Premier, an AI-enabled ultrasound system, and acquired Intelligent Ultrasound Group PLC's clinical AI software business to enhance its ultrasound portfolio [6] - The company also introduced Venue Sprint, a portable ultrasound system designed for point-of-care use, equipped with advanced AI tools [6][7]

GE Healthcare booth is seen ahead of the 2022 China International Fair for Trade in Services (CIFTIS) at China National Convention Center on August 28, 2022 in Beijing, China."For cancer patients, the treatment journey can last years and involve numerous doctor visits," he said.CareIntellect for Oncology will be able to summarize clinical reports and identify when patients are deviating from their treatment plans, Kass-Hout said. The system can flag when a patient misses a lab test, for instance, so that th ...

GE HealthCare (GEHC) completed the acquisition of Intelligent Ultrasound Group PLC's clinical artificial intelligence (AI) software business, a move aimed at reshaping its ultrasound portfolio. The deal, signed in July 2024, is valued at $51 million and aligns with GE HealthCare's broader strategy of integrating AI to enhance patient outcomes, improve clinical workflows and advance medical imaging. This acquisition, along with the earlier deals, is set to strengthen GE HealthCare's capabilities in the compe ...

GE Healthcare's (GEHC) MIM Software recently announced the receipt of FDA clearance for its Monte Carlo Dosimetry, marking a significant advancement in theranostics. This innovative solution is designed to improve the precision of radiation dose calculations for personalized treatment plans in nuclear medicine, particularly for patients receiving radiopharmaceutical therapies. The technology is pivotal in tailoring treatments specifically to the individual needs of patients, thereby maximizing therapeutic b ...

Shares of GE HealthCare Technologies Inc (NASDAQ:GEHC), a spinoff of General Electric (GE), are down 1.9% before the opening bell after a bear note from UBS. The analyst downgraded GEHC to "sell" from "neutral," citing worries over near- to mid-term growth potential and vulnerability to competition in the Chinese Medtech market. Of the 18 brokerages covering GE HealthCare stock, 11 carried a "strong buy" recommendation coming into today, while the remaining seven rated it a lukewarm "hold." This leaves plen ...

GE HealthCare Technologies, Inc (GEHC) has introduced Venue Sprint, a new portable ultrasound system designed to meet the growing demand for point-of-care ultrasound across various healthcare settings. Equipped with powerful Venue software, AI-enabled tools and wireless Vscan Air dual-probes, the Venue Sprint delivers high-quality imaging and real-time insights in critical care, emergency medicine and medical transport environments. The device enhances workflow efficiency by simplifying learning, offering e ...

Financial Data and Key Metrics Changes - In Q2 2024, the company reported revenues of $4.8 billion, reflecting a 1% organic growth year-over-year, compared to 9% growth in Q2 2023 [9][10] - Adjusted EBIT margin increased to 15.3%, up 60 basis points year-over-year, driven by improvements in gross margin [9][10] - Adjusted EPS was $1, representing a 9% increase year-over-year, attributed to adjusted EBIT growth and lower interest expenses [9][10] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics (PDx) segment saw a strong organic growth of 14%, driven by volume, pricing, and new product introductions [10][14] - Imaging segment experienced flat organic revenue growth, impacted by market headwinds in China, but EBIT margin improved by 40 basis points year-over-year [12][13] - Ultrasound segment reported a 1% decline in organic revenue, with EBIT margin decreasing by 120 basis points due to lower sales in China and inflation [13] - Patient Care Solutions had a 1% organic revenue growth, with EBIT margin decreasing by 90 basis points year-over-year [13] Market Data and Key Metrics Changes - Excluding China, global revenue growth was 4%, and orders growth was 6% [3][9] - The company anticipates continued sales decline in China for the year, leading to a reduction in full-year organic revenue growth guidance to 1% to 2% [4][16] - The U.S. market showed robust performance with over $800 million in multimodality equipment contracts secured [8][9] Company Strategy and Development Direction - The company is focusing on lean initiatives and continuous improvement to enhance customer value and eliminate waste [6][7] - Strategic investments are being made in AI tools and collaborations, including an acquisition of Intelligent Ultrasound's AI division and a partnership with Amazon Web Services [8][9] - The company is optimistic about the long-term potential of the China market despite current challenges, viewing it as an attractive opportunity [5][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in medium-term goals, emphasizing the importance of core changes in commercial execution and product innovation [34][35] - The company expects a recovery in the China market orders later in the year, despite current headwinds [5][26] - Management highlighted a strong backlog of $19 billion and a healthy pipeline for growth in the U.S. market [22][23] Other Important Information - The company is maintaining its EPS guidance for the year despite revenue reductions, indicating strong execution on cost initiatives [5][16] - Free cash flow was negative $182 million in Q2 due to timing of payments, but is expected to improve in the second half of the year [15][16] Q&A Session Summary Question: Understanding the pace of opening new orders from the stimulus program in China - Management indicated that the rollout of the stimulus program is taking longer than expected, with growth anticipated to begin in late 2024 [25][26] Question: How to maintain margins and EPS despite revenue reduction - Management attributed the ability to maintain margins and EPS to successful cost initiatives and productivity improvements [29][30] Question: Outlook for 2025 and potential catch-up from China - Management expressed confidence in mid-term goals and indicated that growth from China in 2025 could exceed previous expectations [34] Question: Insights on orders and bookings, particularly in the U.S. market - Management noted strong orders growth in the U.S. market, with a robust pipeline and positive customer sentiment regarding capital investments [38][39] Question: Long-term opportunity for contrast media and molecular imaging markets - Management is optimistic about the growth potential for products like Vizamyl and Flurpiridaz, especially with new reimbursement rules [59][61]

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.04%. A quarter ago, it was expected that this medical technology company would post earnings of $0.90 per share when it actually produced earnings of $0.90, delivering no surprise. Over the last four qua ...